Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2025-12-25 @ 1:46 AM
NCT ID:
NCT00274794
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Patients with B-cell malignancies who are appropriate candidates for high-dose chemotherapy and autologous stem cell transplantation and meet 1 of the following criteria:
* Relapsed or refractory B-cell non-Hodgkin's Lymphoma (NHL)
* Patients with B-cell NHL in first remission and who have significant risk for later relapse
* Patients with other B-cell malignancies otherwise eligible for autologous stem cell transplantation
PATIENT CHARACTERISTICS:
* Life expectancy at least 2 months
* Cardiac ejection fraction ≥ 45%
* DLCO ≥ 45%
* Creatinine \< 2.0 mg/dL
* Bilirubin \< 2.0 mg/dL
* AST \< 2 times normal
* Platelet count ≥ 50,000/mm\^3
* Absolute neutrophil count ≥ 1,500/mm\^3
* Absolute lymphocyte count ≤ 10,000/mm\^3
* HIV negative
* No severe medical or psychiatric illnesses
* Not pregnant or nursing
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
* More than 8 weeks since prior rituximab
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00274794
Study Brief:
Protocol Section:
NCT00274794